Access the full text.
Sign up today, get DeepDyve free for 14 days.
S. Bémelmans, K. Tromp, E. Bunnik, R. Milne, S. Badger, C. Brayne, M. Schermer, E. Richard (2016)
Psychological, behavioral and social effects of disclosing Alzheimer’s disease biomarkers to research participants: a systematic reviewAlzheimer's Research & Therapy, 8
( Brookmeyer R , Abdalla N. Estimation of lifetime risks of Alzheimer's disease dementia using biomarkers for preclinical disease. Alzheimers Dement. 2018;14(8):981‐988.29802030)
Brookmeyer R , Abdalla N. Estimation of lifetime risks of Alzheimer's disease dementia using biomarkers for preclinical disease. Alzheimers Dement. 2018;14(8):981‐988.29802030Brookmeyer R , Abdalla N. Estimation of lifetime risks of Alzheimer's disease dementia using biomarkers for preclinical disease. Alzheimers Dement. 2018;14(8):981‐988.29802030, Brookmeyer R , Abdalla N. Estimation of lifetime risks of Alzheimer's disease dementia using biomarkers for preclinical disease. Alzheimers Dement. 2018;14(8):981‐988.29802030
J. Rabin, A. Schultz, T. Hedden, A. Viswanathan, G. Marshall, Emily Kilpatrick, H. Klein, R. Buckley, Hyun-Sik Yang, M. Properzi, Vaishnavi Rao, D. Kirn, K. Papp, D. Rentz, Keith Johnson, R. Sperling, J. Chhatwal (2018)
Interactive Associations of Vascular Risk and &bgr;-Amyloid Burden With Cognitive Decline in Clinically Normal Elderly Individuals: Findings From the Harvard Aging Brain StudyJAMA Neurology, 75
Y. Lim, P. Maruff, C. Getter, P. Snyder (2016)
Disclosure of positron emission tomography amyloid imaging results: A preliminary study of safety and tolerabilityAlzheimer's & Dementia, 12
R. Sperling, M. Donohue, R. Raman, Chung‐Kai Sun, R. Yaari, K. Holdridge, E. Siemers, Keith Johnson, P. Aisen (2020)
Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals.JAMA neurology
(2019)
The biggest problem with at‐home genetic testing services is hiding in plain sight
( Kim SYH , Karlawish J , Berkman BE . Ethics of genetic and biomarker test disclosures in neurodegenerative disease prevention trials. Neurology. 2015;84(14):1488‐1494.25762713)
Kim SYH , Karlawish J , Berkman BE . Ethics of genetic and biomarker test disclosures in neurodegenerative disease prevention trials. Neurology. 2015;84(14):1488‐1494.25762713Kim SYH , Karlawish J , Berkman BE . Ethics of genetic and biomarker test disclosures in neurodegenerative disease prevention trials. Neurology. 2015;84(14):1488‐1494.25762713, Kim SYH , Karlawish J , Berkman BE . Ethics of genetic and biomarker test disclosures in neurodegenerative disease prevention trials. Neurology. 2015;84(14):1488‐1494.25762713
( Largent EA , Harkins K , van Dyck CH , Hachey S , Sankar P , Karlawish J. Cognitively unimpaired adults’ reactions to disclosure of amyloid PET scan results. PLOS ONE. 2020;15(2):e0229137.32053667)
Largent EA , Harkins K , van Dyck CH , Hachey S , Sankar P , Karlawish J. Cognitively unimpaired adults’ reactions to disclosure of amyloid PET scan results. PLOS ONE. 2020;15(2):e0229137.32053667Largent EA , Harkins K , van Dyck CH , Hachey S , Sankar P , Karlawish J. Cognitively unimpaired adults’ reactions to disclosure of amyloid PET scan results. PLOS ONE. 2020;15(2):e0229137.32053667, Largent EA , Harkins K , van Dyck CH , Hachey S , Sankar P , Karlawish J. Cognitively unimpaired adults’ reactions to disclosure of amyloid PET scan results. PLOS ONE. 2020;15(2):e0229137.32053667
( Ott BR , Pelosi MA , Tremont G , Snyder PJ. A survey of knowledge and views concerning genetic and amyloid positron emission tomography status disclosure. Alzheimers Dement (N Y). 2016;2(1):23‐29.27019867)
Ott BR , Pelosi MA , Tremont G , Snyder PJ. A survey of knowledge and views concerning genetic and amyloid positron emission tomography status disclosure. Alzheimers Dement (N Y). 2016;2(1):23‐29.27019867Ott BR , Pelosi MA , Tremont G , Snyder PJ. A survey of knowledge and views concerning genetic and amyloid positron emission tomography status disclosure. Alzheimers Dement (N Y). 2016;2(1):23‐29.27019867, Ott BR , Pelosi MA , Tremont G , Snyder PJ. A survey of knowledge and views concerning genetic and amyloid positron emission tomography status disclosure. Alzheimers Dement (N Y). 2016;2(1):23‐29.27019867
E. Largent, K. Harkins, C. Dyck, Sara Hachey, P. Sankar, J. Karlawish (2020)
Cognitively unimpaired adults’ reactions to disclosure of amyloid PET scan resultsPLoS ONE, 15
( Jack CR , Bennett DA , Blennow K , et al. NIA‐AA Research Framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14(4):535‐562.29653606)
Jack CR , Bennett DA , Blennow K , et al. NIA‐AA Research Framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14(4):535‐562.29653606Jack CR , Bennett DA , Blennow K , et al. NIA‐AA Research Framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14(4):535‐562.29653606, Jack CR , Bennett DA , Blennow K , et al. NIA‐AA Research Framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14(4):535‐562.29653606
( Harrington KD , Lim YY , Ames D , et al. Amyloid β–associated cognitive decline in the absence of clinical disease progression and systemic illness. Alzheimers Dement (Amst). 2017;8:156‐164.28761926)
Harrington KD , Lim YY , Ames D , et al. Amyloid β–associated cognitive decline in the absence of clinical disease progression and systemic illness. Alzheimers Dement (Amst). 2017;8:156‐164.28761926Harrington KD , Lim YY , Ames D , et al. Amyloid β–associated cognitive decline in the absence of clinical disease progression and systemic illness. Alzheimers Dement (Amst). 2017;8:156‐164.28761926, Harrington KD , Lim YY , Ames D , et al. Amyloid β–associated cognitive decline in the absence of clinical disease progression and systemic illness. Alzheimers Dement (Amst). 2017;8:156‐164.28761926
( Harkins K , Sankar P , Sperling R , et al. Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants. Alzheimers Res Ther. 2015;7(1):26.25969699)
Harkins K , Sankar P , Sperling R , et al. Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants. Alzheimers Res Ther. 2015;7(1):26.25969699Harkins K , Sankar P , Sperling R , et al. Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants. Alzheimers Res Ther. 2015;7(1):26.25969699, Harkins K , Sankar P , Sperling R , et al. Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants. Alzheimers Res Ther. 2015;7(1):26.25969699
( Risk reduction of cognitive decline and dementia: WHO guidelines . Geneva: World Health Organization. 2019 License: CC BY-NC-SA 3.0 IGO. Available from: https://www.ncbi.nlm.nih.gov/books/NBK542796/ )
Risk reduction of cognitive decline and dementia: WHO guidelines . Geneva: World Health Organization. 2019 License: CC BY-NC-SA 3.0 IGO. Available from: https://www.ncbi.nlm.nih.gov/books/NBK542796/Risk reduction of cognitive decline and dementia: WHO guidelines . Geneva: World Health Organization. 2019 License: CC BY-NC-SA 3.0 IGO. Available from: https://www.ncbi.nlm.nih.gov/books/NBK542796/ , Risk reduction of cognitive decline and dementia: WHO guidelines . Geneva: World Health Organization. 2019 License: CC BY-NC-SA 3.0 IGO. Available from: https://www.ncbi.nlm.nih.gov/books/NBK542796/
( Lim YY , Maruff P , Getter C , Snyder PJ. Disclosure of positron emission tomography amyloid imaging results: a preliminary study of safety and tolerability. Alzheimers Dement. 2016;12(4):454‐458.26750717)
Lim YY , Maruff P , Getter C , Snyder PJ. Disclosure of positron emission tomography amyloid imaging results: a preliminary study of safety and tolerability. Alzheimers Dement. 2016;12(4):454‐458.26750717Lim YY , Maruff P , Getter C , Snyder PJ. Disclosure of positron emission tomography amyloid imaging results: a preliminary study of safety and tolerability. Alzheimers Dement. 2016;12(4):454‐458.26750717, Lim YY , Maruff P , Getter C , Snyder PJ. Disclosure of positron emission tomography amyloid imaging results: a preliminary study of safety and tolerability. Alzheimers Dement. 2016;12(4):454‐458.26750717
( Burns JM , Johnson DK , Liebmann EP , Bothwell RJ , Morris JK , Vidoni ED. Safety of disclosing amyloid status in cognitively normal older adults. Alzheimers Dement. 2017;13(9):1024‐1030.28263740)
Burns JM , Johnson DK , Liebmann EP , Bothwell RJ , Morris JK , Vidoni ED. Safety of disclosing amyloid status in cognitively normal older adults. Alzheimers Dement. 2017;13(9):1024‐1030.28263740Burns JM , Johnson DK , Liebmann EP , Bothwell RJ , Morris JK , Vidoni ED. Safety of disclosing amyloid status in cognitively normal older adults. Alzheimers Dement. 2017;13(9):1024‐1030.28263740, Burns JM , Johnson DK , Liebmann EP , Bothwell RJ , Morris JK , Vidoni ED. Safety of disclosing amyloid status in cognitively normal older adults. Alzheimers Dement. 2017;13(9):1024‐1030.28263740
T. Ngandu, J. Lehtisalo, A. Solomon, E. Levälahti, S. Ahtiluoto, R. Antikainen, L. Bäckman, T. Hänninen, A. Jula, T. Laatikainen, J. Lindström, F. Mangialasche, T. Paajanen, S. Pajala, Markku Peltonen, R. Rauramaa, A. Stigsdotter-Neely, T. Strandberg, J. Tuomilehto, H. Soininen, M. Kivipelto (2015)
A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trialThe Lancet, 385
( Bemelmans S , Tromp K , Bunnik EM , et al. Psychological, behavioral and social effects of disclosing Alzheimer's disease biomarkers to research participants: a systematic review. Alzheimers Res Ther. 2016;8:46.27832826)
Bemelmans S , Tromp K , Bunnik EM , et al. Psychological, behavioral and social effects of disclosing Alzheimer's disease biomarkers to research participants: a systematic review. Alzheimers Res Ther. 2016;8:46.27832826Bemelmans S , Tromp K , Bunnik EM , et al. Psychological, behavioral and social effects of disclosing Alzheimer's disease biomarkers to research participants: a systematic review. Alzheimers Res Ther. 2016;8:46.27832826, Bemelmans S , Tromp K , Bunnik EM , et al. Psychological, behavioral and social effects of disclosing Alzheimer's disease biomarkers to research participants: a systematic review. Alzheimers Res Ther. 2016;8:46.27832826
( Bowman Rogers M , ‘Reports of My Death Are Greatly Exaggerated.’ Signed, Aducanumab. AlzForum, Accessed March 23, 2020 https://www.alzforum.org/news/research-news/reports-my-death-are-greatly-exaggerated-signed-aducanumab )
Bowman Rogers M , ‘Reports of My Death Are Greatly Exaggerated.’ Signed, Aducanumab. AlzForum, Accessed March 23, 2020 https://www.alzforum.org/news/research-news/reports-my-death-are-greatly-exaggerated-signed-aducanumabBowman Rogers M , ‘Reports of My Death Are Greatly Exaggerated.’ Signed, Aducanumab. AlzForum, Accessed March 23, 2020 https://www.alzforum.org/news/research-news/reports-my-death-are-greatly-exaggerated-signed-aducanumab , Bowman Rogers M , ‘Reports of My Death Are Greatly Exaggerated.’ Signed, Aducanumab. AlzForum, Accessed March 23, 2020 https://www.alzforum.org/news/research-news/reports-my-death-are-greatly-exaggerated-signed-aducanumab
( Chao S , Roberts JS , Marteau TM , Silliman R , Cupples LA , Green RC. Health behavior changes after genetic risk assessment for Alzheimer disease: the REVEAL Study. Alzheimer Dis Assoc Disord. 2008;22(1):94‐97.18317253)
Chao S , Roberts JS , Marteau TM , Silliman R , Cupples LA , Green RC. Health behavior changes after genetic risk assessment for Alzheimer disease: the REVEAL Study. Alzheimer Dis Assoc Disord. 2008;22(1):94‐97.18317253Chao S , Roberts JS , Marteau TM , Silliman R , Cupples LA , Green RC. Health behavior changes after genetic risk assessment for Alzheimer disease: the REVEAL Study. Alzheimer Dis Assoc Disord. 2008;22(1):94‐97.18317253, Chao S , Roberts JS , Marteau TM , Silliman R , Cupples LA , Green RC. Health behavior changes after genetic risk assessment for Alzheimer disease: the REVEAL Study. Alzheimer Dis Assoc Disord. 2008;22(1):94‐97.18317253
( Ngandu T , Lehtisalo J , Solomon A , et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at‐risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015;385(9984):2255‐2263.25771249)
Ngandu T , Lehtisalo J , Solomon A , et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at‐risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015;385(9984):2255‐2263.25771249Ngandu T , Lehtisalo J , Solomon A , et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at‐risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015;385(9984):2255‐2263.25771249, Ngandu T , Lehtisalo J , Solomon A , et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at‐risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015;385(9984):2255‐2263.25771249
J. Gooblar, C. Roe, Natalie Selsor, M. Gabel, J. Morris (2015)
Attitudes of Research Participants and the General Public Regarding Disclosure of Alzheimer Disease Research Results.JAMA neurology, 72 12
M. Shulman, K. Harkins, R. Green, J. Karlawish (2013)
Using AD biomarker research results for clinical careNeurology, 81
Arno Wilde, W. Flier, W. Pelkmans, F. Bouwman, J. Verwer, C. Groot, Marieke Buchem, M. Zwan, R. Ossenkoppele, M. Yaqub, M. Kunneman, E. Smets, F. Barkhof, A. Lammertsma, A. Stephens, Erik Lier, G. Biessels, B. Berckel, P. Scheltens (2018)
Association of Amyloid Positron Emission Tomography With Changes in Diagnosis and Patient Treatment in an Unselected Memory Clinic Cohort: The ABIDE ProjectJAMA Neurology, 75
( Morris JC , Schindler SE , McCue LM , et al. Assessment of racial disparities in biomarkers for Alzheimer disease. JAMA Neurol. 2019;76(3):264‐273.30615028)
Morris JC , Schindler SE , McCue LM , et al. Assessment of racial disparities in biomarkers for Alzheimer disease. JAMA Neurol. 2019;76(3):264‐273.30615028Morris JC , Schindler SE , McCue LM , et al. Assessment of racial disparities in biomarkers for Alzheimer disease. JAMA Neurol. 2019;76(3):264‐273.30615028, Morris JC , Schindler SE , McCue LM , et al. Assessment of racial disparities in biomarkers for Alzheimer disease. JAMA Neurol. 2019;76(3):264‐273.30615028
Taisei Wake, H. Tabuchi, K. Funaki, D. Ito, B. Yamagata, T. Yoshizaki, M. Kameyama, T. Nakahara, K. Murakami, M. Jinzaki, M. Mimura (2017)
The psychological impact of disclosing amyloid status to Japanese elderly: a preliminary study on asymptomatic patients with subjective cognitive declineInternational Psychogeriatrics, 30
M. Ikonomovic, W. Klunk, E. Abrahamson, C. Mathis, J. Price, N. Tsopelas, B. Lopresti, S. Ziolko, W. Bi, W. Paljug, M. Debnath, C. Hope, Barbara Isanski, R. Hamilton, S. DeKosky (2008)
Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's diseaseBrain, 131
D. Messner (2011)
Informed choice in direct-to-consumer genetic testing for Alzheimer and other diseases: lessons from two casesNew Genetics and Society, 30
( Messner DA. Informed choice in direct‐to‐consumer genetic testing for Alzheimer and other diseases: lessons from two cases. New Genet Soc. 2011;30(1):59‐72.21603253)
Messner DA. Informed choice in direct‐to‐consumer genetic testing for Alzheimer and other diseases: lessons from two cases. New Genet Soc. 2011;30(1):59‐72.21603253Messner DA. Informed choice in direct‐to‐consumer genetic testing for Alzheimer and other diseases: lessons from two cases. New Genet Soc. 2011;30(1):59‐72.21603253, Messner DA. Informed choice in direct‐to‐consumer genetic testing for Alzheimer and other diseases: lessons from two cases. New Genet Soc. 2011;30(1):59‐72.21603253
S. Garrett, Darius McDaniel, Malik Obideen, Antoine Trammell, L. Shaw, F. Goldstein, I. Hajjar (2019)
Racial Disparity in Cerebrospinal Fluid Amyloid and Tau Biomarkers and Associated Cutoffs for Mild Cognitive ImpairmentJAMA Network Open, 2
( Zhou Y , Elashoff D , Kremen S , Teng E , Karlawish J , Grill JD , African Americans are less likely to enroll in preclinical Alzheimer's disease clinical trials. Alzheimers Dement (N Y). 2016;3(1):57‐64.29067319)
Zhou Y , Elashoff D , Kremen S , Teng E , Karlawish J , Grill JD , African Americans are less likely to enroll in preclinical Alzheimer's disease clinical trials. Alzheimers Dement (N Y). 2016;3(1):57‐64.29067319Zhou Y , Elashoff D , Kremen S , Teng E , Karlawish J , Grill JD , African Americans are less likely to enroll in preclinical Alzheimer's disease clinical trials. Alzheimers Dement (N Y). 2016;3(1):57‐64.29067319, Zhou Y , Elashoff D , Kremen S , Teng E , Karlawish J , Grill JD , African Americans are less likely to enroll in preclinical Alzheimer's disease clinical trials. Alzheimers Dement (N Y). 2016;3(1):57‐64.29067319
Richard Milne, E. Bunnik, Ana Diaz, E. Richard, S. Badger, D. Gove, J. Georges, K. Fauria, J. Molinuevo, Katie Wells, C. Ritchie, C. Brayne (2018)
Perspectives on Communicating Biomarker-Based Assessments of Alzheimer’s Disease to Cognitively Healthy Individuals2Journal of Alzheimer's Disease, 62
P. Nelson, H. Braak, W. Markesbery (2009)
Neuropathology and Cognitive Impairment in Alzheimer Disease: A Complex but Coherent RelationshipJournal of Neuropathology and Experimental Neurology, 68
( Nebeker C , Leow A , Moore R. From Return of Information to return of value: ethical considerations when sharing individual‐level research data. J Alzheimers Dis. 2019;71:1‐8.31322565)
Nebeker C , Leow A , Moore R. From Return of Information to return of value: ethical considerations when sharing individual‐level research data. J Alzheimers Dis. 2019;71:1‐8.31322565Nebeker C , Leow A , Moore R. From Return of Information to return of value: ethical considerations when sharing individual‐level research data. J Alzheimers Dis. 2019;71:1‐8.31322565, Nebeker C , Leow A , Moore R. From Return of Information to return of value: ethical considerations when sharing individual‐level research data. J Alzheimers Dis. 2019;71:1‐8.31322565
J. Grill, R. Raman, K. Ernstrom, D. Sultzer, J. Burns, M. Donohue, Keith Johnson, P. Aisen, R. Sperling, J. Karlawish (2020)
Short-term Psychological Outcomes of Disclosing Amyloid Imaging Results to Research Participants Who Do Not Have Cognitive Impairment.JAMA neurology
J. Burns, David Johnson, Edward Liebmann, R. Bothwell, J. Morris, E. Vidoni (2017)
Safety of disclosing amyloid status in cognitively normal older adultsAlzheimer's & Dementia, 13
E. Bunnik, E. Richard, Richard Milne, M. Schermer (2018)
On the personal utility of Alzheimer’s disease-related biomarker testing in the research contextJournal of Medical Ethics, 44
( Williams MM , Scharff DP , Mathews KJ , et al. Barriers and facilitators of African American participation in Alzheimer disease biomarker research. Alzheimer Dis Assoc Disord. 2010;24 Suppl:S24‐29.20711059)
Williams MM , Scharff DP , Mathews KJ , et al. Barriers and facilitators of African American participation in Alzheimer disease biomarker research. Alzheimer Dis Assoc Disord. 2010;24 Suppl:S24‐29.20711059Williams MM , Scharff DP , Mathews KJ , et al. Barriers and facilitators of African American participation in Alzheimer disease biomarker research. Alzheimer Dis Assoc Disord. 2010;24 Suppl:S24‐29.20711059, Williams MM , Scharff DP , Mathews KJ , et al. Barriers and facilitators of African American participation in Alzheimer disease biomarker research. Alzheimer Dis Assoc Disord. 2010;24 Suppl:S24‐29.20711059
Yan Zhou, D. Elashoff, S. Kremen, E. Teng, J. Karlawish, J. Grill (2016)
African Americans are less likely to enroll in preclinical Alzheimer's disease clinical trialsAlzheimer's & Dementia : Translational Research & Clinical Interventions, 3
M. Mielke (2018)
Sex and Gender Differences in Alzheimer's Disease Dementia.The Psychiatric times, 35 11
( Roberts RO , Aakre JA , Kremers WK , et al. Prevalence and outcomes of amyloid positivity among persons without dementia in a longitudinal, population‐based setting. JAMA Neurol. 2018;75(8):970‐979.29710225)
Roberts RO , Aakre JA , Kremers WK , et al. Prevalence and outcomes of amyloid positivity among persons without dementia in a longitudinal, population‐based setting. JAMA Neurol. 2018;75(8):970‐979.29710225Roberts RO , Aakre JA , Kremers WK , et al. Prevalence and outcomes of amyloid positivity among persons without dementia in a longitudinal, population‐based setting. JAMA Neurol. 2018;75(8):970‐979.29710225, Roberts RO , Aakre JA , Kremers WK , et al. Prevalence and outcomes of amyloid positivity among persons without dementia in a longitudinal, population‐based setting. JAMA Neurol. 2018;75(8):970‐979.29710225
( Betthauser TJ , Koscik RL , Jonaitis EM , et al. Amyloid and tau imaging biomarkers explain cognitive decline from late middle‐age. Brain. 2020;143(1):320‐335.31886494)
Betthauser TJ , Koscik RL , Jonaitis EM , et al. Amyloid and tau imaging biomarkers explain cognitive decline from late middle‐age. Brain. 2020;143(1):320‐335.31886494Betthauser TJ , Koscik RL , Jonaitis EM , et al. Amyloid and tau imaging biomarkers explain cognitive decline from late middle‐age. Brain. 2020;143(1):320‐335.31886494, Betthauser TJ , Koscik RL , Jonaitis EM , et al. Amyloid and tau imaging biomarkers explain cognitive decline from late middle‐age. Brain. 2020;143(1):320‐335.31886494
Monique Williams, D. Scharff, K. Mathews, Jonathan Hoffsuemmer, P. Jackson, J. Morris, Dorothy Edwards (2010)
Barriers and Facilitators of African American Participation in Alzheimer Disease Biomarker ResearchAlzheimer Disease & Associated Disorders, 24
( Wake T , Tabuchi H , Funaki K , et al. The psychological impact of disclosing amyloid status to Japanese elderly: a preliminary study on asymptomatic patients with subjective cognitive decline. Int Psychogeriatr. 2018;30(5):635‐639.29094656)
Wake T , Tabuchi H , Funaki K , et al. The psychological impact of disclosing amyloid status to Japanese elderly: a preliminary study on asymptomatic patients with subjective cognitive decline. Int Psychogeriatr. 2018;30(5):635‐639.29094656Wake T , Tabuchi H , Funaki K , et al. The psychological impact of disclosing amyloid status to Japanese elderly: a preliminary study on asymptomatic patients with subjective cognitive decline. Int Psychogeriatr. 2018;30(5):635‐639.29094656, Wake T , Tabuchi H , Funaki K , et al. The psychological impact of disclosing amyloid status to Japanese elderly: a preliminary study on asymptomatic patients with subjective cognitive decline. Int Psychogeriatr. 2018;30(5):635‐639.29094656
R. Brookmeyer, Nada Abdalla (2018)
Estimation of lifetime risks of Alzheimer's disease dementia using biomarkers for preclinical diseaseAlzheimer's & Dementia, 14
MB Shulman, K Harkins, RC Green, J Karlawish (2013)
Using AD biomarker research results for clinical care: a survey of ADNI investigators, 81
Arno Wilde, Marieke Buchem, R. Otten, F. Bouwman, A. Stephens, F. Barkhof, P. Scheltens, W. Flier (2018)
Disclosure of amyloid positron emission tomography results to individuals without dementia: a systematic reviewAlzheimer's Research & Therapy, 10
( Foley KE. The biggest problem with at‐home genetic testing services is hiding in plain sight. Quartz. 2019; Accessed April 15, 2020. https://qz.com/1605697/the-trouble-with-the-design-of-23andmes-genetic-test-results/ )
Foley KE. The biggest problem with at‐home genetic testing services is hiding in plain sight. Quartz. 2019; Accessed April 15, 2020. https://qz.com/1605697/the-trouble-with-the-design-of-23andmes-genetic-test-results/Foley KE. The biggest problem with at‐home genetic testing services is hiding in plain sight. Quartz. 2019; Accessed April 15, 2020. https://qz.com/1605697/the-trouble-with-the-design-of-23andmes-genetic-test-results/ , Foley KE. The biggest problem with at‐home genetic testing services is hiding in plain sight. Quartz. 2019; Accessed April 15, 2020. https://qz.com/1605697/the-trouble-with-the-design-of-23andmes-genetic-test-results/
L. Clark, S. Berman, D. Norton, R. Koscik, E. Jonaitis, K. Blennow, B. Bendlin, S. Asthana, Sterling Johnson, H. Zetterberg, C. Carlsson (2017)
Age-accelerated cognitive decline in asymptomatic adults with CSF β-amyloidNeurology, 90
Camille Nebeker, A. Leow, R. Moore (2019)
From Return of Information to Return of Value: Ethical Considerations when Sharing Individual-Level Research Data.Journal of Alzheimer's disease : JAD
( Rabin JS , Schultz AP , Hedden T , et al. Interactive Associations of vascular risk and β‐amyloid burden with cognitive decline in clinically normal elderly individuals. JAMA Neurol. 2018;75(9):1124‐1131.29799986)
Rabin JS , Schultz AP , Hedden T , et al. Interactive Associations of vascular risk and β‐amyloid burden with cognitive decline in clinically normal elderly individuals. JAMA Neurol. 2018;75(9):1124‐1131.29799986Rabin JS , Schultz AP , Hedden T , et al. Interactive Associations of vascular risk and β‐amyloid burden with cognitive decline in clinically normal elderly individuals. JAMA Neurol. 2018;75(9):1124‐1131.29799986, Rabin JS , Schultz AP , Hedden T , et al. Interactive Associations of vascular risk and β‐amyloid burden with cognitive decline in clinically normal elderly individuals. JAMA Neurol. 2018;75(9):1124‐1131.29799986
( Nelson PT , Braak H , Markesbery WR. Neuropathology and cognitive impairment in Alzheimer disease: a complex but coherent relationship. J Neuropathol Exp Neurol. 2009;68(1):1‐14.19104448)
Nelson PT , Braak H , Markesbery WR. Neuropathology and cognitive impairment in Alzheimer disease: a complex but coherent relationship. J Neuropathol Exp Neurol. 2009;68(1):1‐14.19104448Nelson PT , Braak H , Markesbery WR. Neuropathology and cognitive impairment in Alzheimer disease: a complex but coherent relationship. J Neuropathol Exp Neurol. 2009;68(1):1‐14.19104448, Nelson PT , Braak H , Markesbery WR. Neuropathology and cognitive impairment in Alzheimer disease: a complex but coherent relationship. J Neuropathol Exp Neurol. 2009;68(1):1‐14.19104448
L. Silverman (1976)
Psychoanalytic theory "the reports of my death are greatly exaggerated".The American psychologist, 31 9
( Stites SD. Cognitively healthy individuals want to know their risk for Alzheimer's disease: what should we do? J Alzheimers Dis. 2018;62(2):499‐501.29480203)
Stites SD. Cognitively healthy individuals want to know their risk for Alzheimer's disease: what should we do? J Alzheimers Dis. 2018;62(2):499‐501.29480203Stites SD. Cognitively healthy individuals want to know their risk for Alzheimer's disease: what should we do? J Alzheimers Dis. 2018;62(2):499‐501.29480203, Stites SD. Cognitively healthy individuals want to know their risk for Alzheimer's disease: what should we do? J Alzheimers Dis. 2018;62(2):499‐501.29480203
( Rabinovici GD , Gatsonis C , Apgar C , et al. Association of amyloid positron emission tomography with subsequent change in clinical management among medicare beneficiaries with mild cognitive impairment or dementia. JAMA. 2019;321(13):1286‐1294.30938796)
Rabinovici GD , Gatsonis C , Apgar C , et al. Association of amyloid positron emission tomography with subsequent change in clinical management among medicare beneficiaries with mild cognitive impairment or dementia. JAMA. 2019;321(13):1286‐1294.30938796Rabinovici GD , Gatsonis C , Apgar C , et al. Association of amyloid positron emission tomography with subsequent change in clinical management among medicare beneficiaries with mild cognitive impairment or dementia. JAMA. 2019;321(13):1286‐1294.30938796, Rabinovici GD , Gatsonis C , Apgar C , et al. Association of amyloid positron emission tomography with subsequent change in clinical management among medicare beneficiaries with mild cognitive impairment or dementia. JAMA. 2019;321(13):1286‐1294.30938796
C. Jack, D. Bennett, K. Blennow, M. Carrillo, B. Dunn, S. Haeberlein, D. Holtzman, W. Jagust, F. Jessen, J. Karlawish, E. Liu, J. Molinuevo, T. Montine, C. Phelps, K. Rankin, C. Rowe, P. Scheltens, E. Siemers, H. Snyder, R. Sperling (2018)
NIA-AA Research Framework: Toward a biological definition of Alzheimer’s diseaseAlzheimer's & dementia : the journal of the Alzheimer's Association, 14
B. Ott, Marissa Pelosi, G. Tremont, P. Snyder (2016)
A survey of knowledge and views concerning genetic and amyloid positron emission tomography status disclosureAlzheimer's & Dementia : Translational Research & Clinical Interventions, 2
( Sperling RA , Donohue MC , Raman R , et al. Association of factors with elevated amyloid burden in clinically normal older individuals. JAMA Neurol. 2020;77(6):735‐745.32250387)
Sperling RA , Donohue MC , Raman R , et al. Association of factors with elevated amyloid burden in clinically normal older individuals. JAMA Neurol. 2020;77(6):735‐745.32250387Sperling RA , Donohue MC , Raman R , et al. Association of factors with elevated amyloid burden in clinically normal older individuals. JAMA Neurol. 2020;77(6):735‐745.32250387, Sperling RA , Donohue MC , Raman R , et al. Association of factors with elevated amyloid burden in clinically normal older individuals. JAMA Neurol. 2020;77(6):735‐745.32250387
( Gooblar J , Roe CM , Selsor NJ , Gabel MJ , Morris JC . Attitudes of research participants and the general public regarding disclosure of Alzheimer disease research results. JAMA Neurol. 2015;72(12):1484‐1490.26501506)
Gooblar J , Roe CM , Selsor NJ , Gabel MJ , Morris JC . Attitudes of research participants and the general public regarding disclosure of Alzheimer disease research results. JAMA Neurol. 2015;72(12):1484‐1490.26501506Gooblar J , Roe CM , Selsor NJ , Gabel MJ , Morris JC . Attitudes of research participants and the general public regarding disclosure of Alzheimer disease research results. JAMA Neurol. 2015;72(12):1484‐1490.26501506, Gooblar J , Roe CM , Selsor NJ , Gabel MJ , Morris JC . Attitudes of research participants and the general public regarding disclosure of Alzheimer disease research results. JAMA Neurol. 2015;72(12):1484‐1490.26501506
K. Harrington, Y. Lim, D. Ames, J. Hassenstab, S. Laws, R. Martins, S. Rainey-Smith, J. Robertson, C. Rowe, O. Salvado, V. Doré, V. Villemagne, P. Snyder, C. Masters, P. Maruff (2017)
Amyloid β–associated cognitive decline in the absence of clinical disease progression and systemic illnessAlzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring, 8
J. Grill, Chelsea Cox, K. Harkins, J. Karlawish (2018)
Reactions to learning a “not elevated” amyloid PET result in a preclinical Alzheimer’s disease trialAlzheimer's Research & Therapy, 10
G. Vanderschaeghe, R. Vandenberghe, K. Dierickx (2019)
Stakeholders’ Views on Early Diagnosis for Alzheimer’s Disease, Clinical Trial Participation and Amyloid PET Disclosure: A Focus Group StudyJournal of Bioethical Inquiry, 16
( Lineweaver TT , Bondi MW , Galasko D , Salmon DP. Effect of Knowledge of APOE genotype on subjective and objective memory performance in healthy older adults. Am J Psychiatry. 2014;171(2):201‐208.24170170)
Lineweaver TT , Bondi MW , Galasko D , Salmon DP. Effect of Knowledge of APOE genotype on subjective and objective memory performance in healthy older adults. Am J Psychiatry. 2014;171(2):201‐208.24170170Lineweaver TT , Bondi MW , Galasko D , Salmon DP. Effect of Knowledge of APOE genotype on subjective and objective memory performance in healthy older adults. Am J Psychiatry. 2014;171(2):201‐208.24170170, Lineweaver TT , Bondi MW , Galasko D , Salmon DP. Effect of Knowledge of APOE genotype on subjective and objective memory performance in healthy older adults. Am J Psychiatry. 2014;171(2):201‐208.24170170
J. Mozersky, P. Sankar, K. Harkins, Sara Hachey, J. Karlawish (2018)
Comprehension of an Elevated Amyloid Positron Emission Tomography Biomarker Result by Cognitively Normal Older AdultsJAMA Neurology, 75
( Clark LR , Berman SE , Norton D , et al. Age‐accelerated cognitive decline in asymptomatic adults with CSF β‐amyloid. Neurology. 2018;90(15):e1306‐e1315.29523644)
Clark LR , Berman SE , Norton D , et al. Age‐accelerated cognitive decline in asymptomatic adults with CSF β‐amyloid. Neurology. 2018;90(15):e1306‐e1315.29523644Clark LR , Berman SE , Norton D , et al. Age‐accelerated cognitive decline in asymptomatic adults with CSF β‐amyloid. Neurology. 2018;90(15):e1306‐e1315.29523644, Clark LR , Berman SE , Norton D , et al. Age‐accelerated cognitive decline in asymptomatic adults with CSF β‐amyloid. Neurology. 2018;90(15):e1306‐e1315.29523644
( Langlois CM , Bradbury A , Wood EM , et al. Alzheimer's Prevention Initiative Generation Program: development of an APOE genetic counseling and disclosure process in the context of clinical trials. Alzheimers Dement (N Y). 2019;5:705‐716.31921963)
Langlois CM , Bradbury A , Wood EM , et al. Alzheimer's Prevention Initiative Generation Program: development of an APOE genetic counseling and disclosure process in the context of clinical trials. Alzheimers Dement (N Y). 2019;5:705‐716.31921963Langlois CM , Bradbury A , Wood EM , et al. Alzheimer's Prevention Initiative Generation Program: development of an APOE genetic counseling and disclosure process in the context of clinical trials. Alzheimers Dement (N Y). 2019;5:705‐716.31921963, Langlois CM , Bradbury A , Wood EM , et al. Alzheimer's Prevention Initiative Generation Program: development of an APOE genetic counseling and disclosure process in the context of clinical trials. Alzheimers Dement (N Y). 2019;5:705‐716.31921963
Elizabeth Morris, A. Chalkidou, A. Hammers, J. Peacock, J. Summers, S. Keevil (2015)
Diagnostic accuracy of 18F amyloid PET tracers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysisEuropean Journal of Nuclear Medicine and Molecular Imaging, 43
R. Green, R. Green, J. Roberts, L. Cupples, N. Relkin, P. Whitehouse, Tamsen Brown, S. Eckert, M. Butson, A. Sadovnick, K. Quaid, Clara Chen, R. Cook-Deegan, L. Farrer (2009)
Disclosure of APOE genotype for risk of Alzheimer's disease.The New England journal of medicine, 361 3
( Mozersky J , Sankar P , Harkins K , Hachey S , Karlawish J. Comprehension of an elevated amyloid positron emission tomography biomarker result by cognitively normal older adults. Jama Neurology. 2018;75(1):44‐50.29059270)
Mozersky J , Sankar P , Harkins K , Hachey S , Karlawish J. Comprehension of an elevated amyloid positron emission tomography biomarker result by cognitively normal older adults. Jama Neurology. 2018;75(1):44‐50.29059270Mozersky J , Sankar P , Harkins K , Hachey S , Karlawish J. Comprehension of an elevated amyloid positron emission tomography biomarker result by cognitively normal older adults. Jama Neurology. 2018;75(1):44‐50.29059270, Mozersky J , Sankar P , Harkins K , Hachey S , Karlawish J. Comprehension of an elevated amyloid positron emission tomography biomarker result by cognitively normal older adults. Jama Neurology. 2018;75(1):44‐50.29059270
E. Mormino, K. Papp (2018)
Amyloid Accumulation and Cognitive Decline in Clinically Normal Older Individuals: Implications for Aging and Early Alzheimer's Disease.Journal of Alzheimer's disease : JAD, 64 s1
Serena Chao, J. Roberts, T. Marteau, R. Silliman, L. Cupples, R. Green (2008)
Health Behavior Changes After Genetic Risk Assessment for Alzheimer Disease: The REVEAL StudyAlzheimer Disease & Associated Disorders, 22
( Garrett SL , McDaniel D , Obideen M , et al. Racial Disparity in cerebrospinal fluid amyloid and tau biomarkers and associated cutoffs for mild cognitive impairment. JAMA Netw Open. 2019;2(12):e1917363.31834392)
Garrett SL , McDaniel D , Obideen M , et al. Racial Disparity in cerebrospinal fluid amyloid and tau biomarkers and associated cutoffs for mild cognitive impairment. JAMA Netw Open. 2019;2(12):e1917363.31834392Garrett SL , McDaniel D , Obideen M , et al. Racial Disparity in cerebrospinal fluid amyloid and tau biomarkers and associated cutoffs for mild cognitive impairment. JAMA Netw Open. 2019;2(12):e1917363.31834392, Garrett SL , McDaniel D , Obideen M , et al. Racial Disparity in cerebrospinal fluid amyloid and tau biomarkers and associated cutoffs for mild cognitive impairment. JAMA Netw Open. 2019;2(12):e1917363.31834392
C. Langlois, A. Bradbury, E. Wood, J. Roberts, Scott Kim, M. Riviere, F. Liu, E. Reiman, P. Tariot, J. Karlawish, J. Langbaum (2019)
Alzheimer's Prevention Initiative Generation Program: Development of an APOE genetic counseling and disclosure process in the context of clinical trialsAlzheimer's & Dementia : Translational Research & Clinical Interventions, 5
K. Harkins, P. Sankar, R. Sperling, J. Grill, R. Green, Keith Johnson, Megan Healy, J. Karlawish (2014)
Development of a process to disclose amyloid imaging results to cognitively normal older adult research participantsAlzheimer's Research & Therapy, 7
( Ikonomovic MD , Klunk WE , Abrahamson EE , et al. Post‐mortem correlates of in vivo PiB‐PET amyloid imaging in a typical case of Alzheimer's disease. Brain. 2008;131(Pt 6):1630‐1645.18339640)
Ikonomovic MD , Klunk WE , Abrahamson EE , et al. Post‐mortem correlates of in vivo PiB‐PET amyloid imaging in a typical case of Alzheimer's disease. Brain. 2008;131(Pt 6):1630‐1645.18339640Ikonomovic MD , Klunk WE , Abrahamson EE , et al. Post‐mortem correlates of in vivo PiB‐PET amyloid imaging in a typical case of Alzheimer's disease. Brain. 2008;131(Pt 6):1630‐1645.18339640, Ikonomovic MD , Klunk WE , Abrahamson EE , et al. Post‐mortem correlates of in vivo PiB‐PET amyloid imaging in a typical case of Alzheimer's disease. Brain. 2008;131(Pt 6):1630‐1645.18339640
JS Rabin, AP Schultz, T Hedden (2018)
Interactive Associations of vascular risk and β‐amyloid burden with cognitive decline in clinically normal elderly individuals, 75
L. Barnes, S. Leurgans, N. Aggarwal, R. Shah, Z. Arvanitakis, B. James, A. Buchman, D. Bennett, J. Schneider (2015)
Mixed pathology is more likely in black than white decedents with Alzheimer dementiaNeurology, 85
( Shulman MB , Harkins K , Green RC , Karlawish J . Using AD biomarker research results for clinical care: a survey of ADNI investigators. Neurology. 2013;81(13):1114‐1121.23966249)
Shulman MB , Harkins K , Green RC , Karlawish J . Using AD biomarker research results for clinical care: a survey of ADNI investigators. Neurology. 2013;81(13):1114‐1121.23966249Shulman MB , Harkins K , Green RC , Karlawish J . Using AD biomarker research results for clinical care: a survey of ADNI investigators. Neurology. 2013;81(13):1114‐1121.23966249, Shulman MB , Harkins K , Green RC , Karlawish J . Using AD biomarker research results for clinical care: a survey of ADNI investigators. Neurology. 2013;81(13):1114‐1121.23966249
( Mormino EC , Papp KV . Amyloid accumulation and cognitive decline in clinically normal older individuals: implications for aging and early Alzheimer's disease. J Alzheimers Dis. 2018;64(Suppl 1):S633‐S646.29782318)
Mormino EC , Papp KV . Amyloid accumulation and cognitive decline in clinically normal older individuals: implications for aging and early Alzheimer's disease. J Alzheimers Dis. 2018;64(Suppl 1):S633‐S646.29782318Mormino EC , Papp KV . Amyloid accumulation and cognitive decline in clinically normal older individuals: implications for aging and early Alzheimer's disease. J Alzheimers Dis. 2018;64(Suppl 1):S633‐S646.29782318, Mormino EC , Papp KV . Amyloid accumulation and cognitive decline in clinically normal older individuals: implications for aging and early Alzheimer's disease. J Alzheimers Dis. 2018;64(Suppl 1):S633‐S646.29782318
Scott Kim, J. Karlawish, B. Berkman (2015)
Ethics of genetic and biomarker test disclosures in neurodegenerative disease prevention trialsNeurology, 84
J. Morris, S. Schindler, Lena McCue, K. Moulder, T. Benzinger, Carlos Cruchaga, A. Fagan, E. Grant, B. Gordon, D. Holtzman, C. Xiong (2019)
Assessment of Racial Disparities in Biomarkers for Alzheimer DiseaseJAMA Neurology, 76
( Barnes LL , Leurgans S , Aggarwal NT , et al. Mixed pathology is more likely in black than white decedents with Alzheimer dementia. Neurology. 2015;85(6):528‐534.26180136)
Barnes LL , Leurgans S , Aggarwal NT , et al. Mixed pathology is more likely in black than white decedents with Alzheimer dementia. Neurology. 2015;85(6):528‐534.26180136Barnes LL , Leurgans S , Aggarwal NT , et al. Mixed pathology is more likely in black than white decedents with Alzheimer dementia. Neurology. 2015;85(6):528‐534.26180136, Barnes LL , Leurgans S , Aggarwal NT , et al. Mixed pathology is more likely in black than white decedents with Alzheimer dementia. Neurology. 2015;85(6):528‐534.26180136
TT Lineweaver, MW Bondi, D Galasko, DP. Salmon (2014)
Effect of Knowledge of APOE genotype on subjective and objective memory performance in healthy older adults, 171
T. Betthauser, R. Koscik, E. Jonaitis, S. Allison, K. Cody, C. Erickson, H. Rowley, C. Stone, Kimberly Mueller, L. Clark, C. Carlsson, N. Chin, S. Asthana, B. Christian, Sterling Johnson (2019)
Amyloid and tau imaging biomarkers explain cognitive decline from late middle-ageBrain, 143
(2020)
‘Reports of My Death Are Greatly Exaggerated.’ Signed, Aducanumab
( Vanderschaeghe G , Schaeverbeke J , Bruffaerts R , Vandenberghe R , Dierickx K. From information to follow‐up: ethical recommendations to facilitate the disclosure of amyloid PET scan results in a research setting. Alzheimers Dement (N Y). 2018;4:243‐251.29955667)
Vanderschaeghe G , Schaeverbeke J , Bruffaerts R , Vandenberghe R , Dierickx K. From information to follow‐up: ethical recommendations to facilitate the disclosure of amyloid PET scan results in a research setting. Alzheimers Dement (N Y). 2018;4:243‐251.29955667Vanderschaeghe G , Schaeverbeke J , Bruffaerts R , Vandenberghe R , Dierickx K. From information to follow‐up: ethical recommendations to facilitate the disclosure of amyloid PET scan results in a research setting. Alzheimers Dement (N Y). 2018;4:243‐251.29955667, Vanderschaeghe G , Schaeverbeke J , Bruffaerts R , Vandenberghe R , Dierickx K. From information to follow‐up: ethical recommendations to facilitate the disclosure of amyloid PET scan results in a research setting. Alzheimers Dement (N Y). 2018;4:243‐251.29955667
( de Wilde A , van der Flier WM , Pelkmans W , et al. Association of amyloid positron emission tomography with changes in diagnosis and patient treatment in an unselected memory clinic cohort: the ABIDE Project. JAMA Neurol. 2018;75(9):1062‐1070.29889941)
de Wilde A , van der Flier WM , Pelkmans W , et al. Association of amyloid positron emission tomography with changes in diagnosis and patient treatment in an unselected memory clinic cohort: the ABIDE Project. JAMA Neurol. 2018;75(9):1062‐1070.29889941de Wilde A , van der Flier WM , Pelkmans W , et al. Association of amyloid positron emission tomography with changes in diagnosis and patient treatment in an unselected memory clinic cohort: the ABIDE Project. JAMA Neurol. 2018;75(9):1062‐1070.29889941, de Wilde A , van der Flier WM , Pelkmans W , et al. Association of amyloid positron emission tomography with changes in diagnosis and patient treatment in an unselected memory clinic cohort: the ABIDE Project. JAMA Neurol. 2018;75(9):1062‐1070.29889941
A. Cohen, G. Rabinovici, C. Mathis, W. Jagust, W. Klunk, M. Ikonomovic (2012)
Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta.Advances in pharmacology, 64
G. Vanderschaeghe, J. Schaeverbeke, R. Bruffaerts, R. Vandenberghe, K. Dierickx (2018)
From information to follow-up: Ethical recommendations to facilitate the disclosure of amyloid PET scan results in a research settingAlzheimer's & Dementia : Translational Research & Clinical Interventions, 4
S. Stites (2018)
Cognitively Healthy Individuals Want to Know Their Risk for Alzheimer's Disease: What Should We Do?Journal of Alzheimer's disease : JAD, 62 2
( Milne R , Bunnik E , Diaz A , et al. Perspectives on Communicating biomarker‐based assessments of Alzheimer's disease to cognitively healthy individuals. J Alzheimers Dis. 2018;62(2):487‐498.29480179)
Milne R , Bunnik E , Diaz A , et al. Perspectives on Communicating biomarker‐based assessments of Alzheimer's disease to cognitively healthy individuals. J Alzheimers Dis. 2018;62(2):487‐498.29480179Milne R , Bunnik E , Diaz A , et al. Perspectives on Communicating biomarker‐based assessments of Alzheimer's disease to cognitively healthy individuals. J Alzheimers Dis. 2018;62(2):487‐498.29480179, Milne R , Bunnik E , Diaz A , et al. Perspectives on Communicating biomarker‐based assessments of Alzheimer's disease to cognitively healthy individuals. J Alzheimers Dis. 2018;62(2):487‐498.29480179
GD Rabinovici, C Gatsonis, C Apgar (2019)
Association of amyloid positron emission tomography with subsequent change in clinical management among medicare beneficiaries with mild cognitive impairment or dementia, 321
( Green RC , Roberts JS , Cupples LA , et al. Disclosure of APOE genotype for risk of Alzheimer's disease. N Engl J Med. 2009;361(3):245‐254.19605829)
Green RC , Roberts JS , Cupples LA , et al. Disclosure of APOE genotype for risk of Alzheimer's disease. N Engl J Med. 2009;361(3):245‐254.19605829Green RC , Roberts JS , Cupples LA , et al. Disclosure of APOE genotype for risk of Alzheimer's disease. N Engl J Med. 2009;361(3):245‐254.19605829, Green RC , Roberts JS , Cupples LA , et al. Disclosure of APOE genotype for risk of Alzheimer's disease. N Engl J Med. 2009;361(3):245‐254.19605829
( Mielke MM. Sex and Gender Differences in Alzheimer's Disease Dementia. Psychiatr Times. 2018;35(11):14‐17.30820070)
Mielke MM. Sex and Gender Differences in Alzheimer's Disease Dementia. Psychiatr Times. 2018;35(11):14‐17.30820070Mielke MM. Sex and Gender Differences in Alzheimer's Disease Dementia. Psychiatr Times. 2018;35(11):14‐17.30820070, Mielke MM. Sex and Gender Differences in Alzheimer's Disease Dementia. Psychiatr Times. 2018;35(11):14‐17.30820070
( Grill JD , Raman R , Ernstrom K , et al. Short‐term psychological outcomes of disclosing amyloid imaging results to research participants who do not have cognitive impairment. JAMA Neurol. Published online August 10, 2020; e202734. 10.1001/jamaneurol.2020.2734 )
Grill JD , Raman R , Ernstrom K , et al. Short‐term psychological outcomes of disclosing amyloid imaging results to research participants who do not have cognitive impairment. JAMA Neurol. Published online August 10, 2020; e202734. 10.1001/jamaneurol.2020.2734Grill JD , Raman R , Ernstrom K , et al. Short‐term psychological outcomes of disclosing amyloid imaging results to research participants who do not have cognitive impairment. JAMA Neurol. Published online August 10, 2020; e202734. 10.1001/jamaneurol.2020.2734 , Grill JD , Raman R , Ernstrom K , et al. Short‐term psychological outcomes of disclosing amyloid imaging results to research participants who do not have cognitive impairment. JAMA Neurol. Published online August 10, 2020; e202734. 10.1001/jamaneurol.2020.2734
( Bunnik EM , Richard E , Milne R , Schermer MHN. On the personal utility of Alzheimer's disease‐related biomarker testing in the research context. J Med Ethics. 2018;44(12):830‐834.30154216)
Bunnik EM , Richard E , Milne R , Schermer MHN. On the personal utility of Alzheimer's disease‐related biomarker testing in the research context. J Med Ethics. 2018;44(12):830‐834.30154216Bunnik EM , Richard E , Milne R , Schermer MHN. On the personal utility of Alzheimer's disease‐related biomarker testing in the research context. J Med Ethics. 2018;44(12):830‐834.30154216, Bunnik EM , Richard E , Milne R , Schermer MHN. On the personal utility of Alzheimer's disease‐related biomarker testing in the research context. J Med Ethics. 2018;44(12):830‐834.30154216
( Cohen AD , Rabinovici GD , Mathis CA , Jagust WJ , Klunk WE , Ikonomovic MD. Using Pittsburgh compound b for in vivo pet imaging of fibrillar amyloid‐beta. Adv Pharmacol. 2012;64:27‐81.22840744)
Cohen AD , Rabinovici GD , Mathis CA , Jagust WJ , Klunk WE , Ikonomovic MD. Using Pittsburgh compound b for in vivo pet imaging of fibrillar amyloid‐beta. Adv Pharmacol. 2012;64:27‐81.22840744Cohen AD , Rabinovici GD , Mathis CA , Jagust WJ , Klunk WE , Ikonomovic MD. Using Pittsburgh compound b for in vivo pet imaging of fibrillar amyloid‐beta. Adv Pharmacol. 2012;64:27‐81.22840744, Cohen AD , Rabinovici GD , Mathis CA , Jagust WJ , Klunk WE , Ikonomovic MD. Using Pittsburgh compound b for in vivo pet imaging of fibrillar amyloid‐beta. Adv Pharmacol. 2012;64:27‐81.22840744
R. Roberts, J. Aakre, W. Kremers, M. Vassilaki, D. Knopman, M. Mielke, Rabe Alhurani, Y. Geda, M. Machulda, P. Coloma, B. Schauble, V. Lowe, C. Jack, R. Petersen (2018)
Prevalence and Outcomes of Amyloid Positivity Among Persons Without Dementia in a Longitudinal, Population-Based SettingJAMA Neurology, 75
Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring – Wiley
Published: Jan 1, 2021
Keywords: ; ; ; ; ;
You can share this free article with as many people as you like with the url below! We hope you enjoy this feature!
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.